Terrestrial gross primary productivity (GPP) is the largest carbon flux in the global carbon cycle and plays a crucial role in terrestrial carbon sequestration. However, historical and future global GPP estimates still vary markedly. In this study, we reduced uncertainties in global GPP estimates by employing an innovative emergent constraint method on remote sensing-based GPP datasets (RS-GPP), using ground-based estimates of GPP from flux towers as the observational constraint. Using this approach, the global GPP in 2001-2014 was estimated to be 126.8 ± 6.4 PgC year, compared to the original RS-GPP ensemble mean of 120.9 ± 10.6 PgC year, which reduced the uncertainty range by 39.6%. Independent space- and time-based (different latitudinal zones, different vegetation types, and individual year) constraints further confirmed the robustness of the global GPP estimate. Building on these insights, we extended our constraints to project global GPP estimates in 2081-2100 under various Shared Socioeconomic Pathway (SSP) scenarios: SSP126 (140.6 ± 9.3 PgC year), SSP245 (153.5 ± 13.4 PgC year), SSP370 (170.7 ± 16.9 PgC year), and SSP585 (194.1 ± 23.2 PgC year). These findings have important implications for understanding and projecting climate change, helping to develop more effective climate policies and carbon reduction strategies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/gcb.17479 | DOI Listing |
Osteoarthritis Cartilage
December 2024
Formation Bio, Inc., Research and Development, New York City, NY, USA; Caduceus Biomedical Consulting, LLC, Durham, NC, USA; Duke University School of Medicine, Department of Medicine, Division of Rheumatology, Durham, NC, USA.
Objectives: Explore a newly defined composite measure of symptom progression for knee osteoarthritis (KOA) in a large, randomized study of a potential disease-modifying osteoarthritis drug (DMOAD).
Design: Using longitudinal KOA studies, a potential composite endpoint of time to symptom progression was defined as the first occurrence of worsening of WOMAC Pain of ≥10 points with no improvement (≤9 point decrease) in WOMAC Function (0-100 scale). A post hoc analysis explored discrimination and association with structural outcomes in the sprifermin FORWARD trial through Years 3 and 5.
Proc Natl Acad Sci U S A
December 2024
Department of Microbiology Immunology and Molecular Genetics, University of California, Los Angeles, CA 90095.
Adenocarcinomas from multiple tissues can converge to treatment-resistant small cell neuroendocrine (SCN) cancers composed of ASCL1, POU2F3, NEUROD1, and YAP1 subtypes. We investigated how mitochondrial metabolism influences SCN cancer (SCNC) progression. Extensive bioinformatics analyses encompassing thousands of patient tumors and human cancer cell lines uncovered enhanced expression of proliferator-activatedreceptor gamma coactivator 1-alpha (PGC-1α), a potent regulator of mitochondrial oxidative phosphorylation (OXPHOS), across several SCNCs.
View Article and Find Full Text PDFCureus
August 2024
Physical Therapy, School of Health Science and Social Welfare, Kibi International University, Takahashi, JPN.
Glob Chang Biol
August 2024
NIOZ Royal Netherlands Institute for Sea Research, Texel, The Netherlands.
Terrestrial gross primary productivity (GPP) is the largest carbon flux in the global carbon cycle and plays a crucial role in terrestrial carbon sequestration. However, historical and future global GPP estimates still vary markedly. In this study, we reduced uncertainties in global GPP estimates by employing an innovative emergent constraint method on remote sensing-based GPP datasets (RS-GPP), using ground-based estimates of GPP from flux towers as the observational constraint.
View Article and Find Full Text PDFJ Gastrointest Cancer
December 2024
Pharmacy Department, First Towakai Hospital, Takatsuki, Japan.
Purpose: The clinical effectiveness of triple chemotherapy consisting of gemcitabine, cisplatin plus either S-1 (GCS), durvalumab (DGC), or pembrolizumab (PGC) as first-line treatment for advanced biliary tract cancer (BTC) has been reported. However, their comparative cost-effectiveness is unclear. We conducted a model-based cost-effectiveness analysis from the perspective of Japanese healthcare payer.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!